XBI is trading 3.38% up now at $159.39 after improving pharmaceutical and biotech R&D demand, a healthier funding environment, and renewed M&A optimism.
- Thermo Fisher highlighted stronger orders and raised its 2026 organic-growth outlook.
- Merck’s $11.3 billion Bio-Techne acquisition reinforced takeover expectations.
- Broader risk appetite supported gains, with major U.S. indices higher on September 17, 2026.